New insights into the functions of Cox-2 in skin and esophageal malignancies.
Journal
Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
25
02
2020
accepted:
28
02
2020
pubmed:
3
4
2020
medline:
3
8
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
Understanding the cellular and molecular mechanisms of tumor initiation and progression for each cancer type is central to making improvements in both prevention and therapy. Identifying the cancer cells of origin and the necessary and sufficient mechanisms of transformation and progression provide opportunities for improved specific clinical interventions. In the last few decades, advanced genetic manipulation techniques have facilitated rapid progress in defining the etiologies of cancers and their cells of origin. Recent studies driven by various groups have provided experimental evidence indicating the cellular origins for each type of skin and esophageal cancer and have identified underlying mechanisms that stem/progenitor cells use to initiate tumor development. Specifically, cyclooxygenase-2 (Cox-2) is associated with tumor initiation and progression in many cancer types. Recent studies provide data demonstrating the roles of Cox-2 in skin and esophageal malignancies, especially in squamous cell carcinomas (SCCs) occurring in both sites. Here, we review experimental evidence aiming to define the origins of skin and esophageal cancers and discuss how Cox-2 contributes to tumorigenesis and differentiation.
Identifiants
pubmed: 32235869
doi: 10.1038/s12276-020-0412-2
pii: 10.1038/s12276-020-0412-2
pmc: PMC7210257
doi:
Substances chimiques
Cyclooxygenase 2
EC 1.14.99.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
538-547Références
Subbaramaiah, K. & Dannenberg, A. J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24, 96–102 (2003).
pubmed: 12559775
Gong, L. et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics. 22, 310–318 (2012).
pubmed: 22336956
pmcid: 3303994
Simões, M. C. F., Sousa, J. J. S. & Pais, A. A. C. C. Skin cancer and new treatment perspectives: a review. Cancer Lett. 357, 8–42 (2015).
pubmed: 25444899
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).
pubmed: 30620402
Guy, G. P. et al. Vital signs: melanoma incidence and mortality trends and projections—United States, 1982–2030. MMWR Morb. Mortal. Wkly. Rep. 64, 591–596 (2015).
pubmed: 26042651
pmcid: 4584771
Blanpain, C. Tracing the cellular origin of cancer. Nat. Cell. Biol. 15, 126–134 (2013).
pubmed: 23334500
White, A. C. & Lowry, W. E. Refining the role for adult stem cells as cancer cells of origin. Trends Cell. Biol. 25, 11–20 (2015).
pubmed: 25242116
Boumahdi, S. & Blanpain, C. CANCER. Tracking the origins of tumorigenesis. Science 351, 453–454 (2016).
pubmed: 26823415
Moon, H., Donahue, L. R. & White, A. C. in Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance (Huiping Liu, H.& Lathia, J. D. eds) 1st edn, Ch. 10 (Elsevier, Cambridge, 2016).
Youssef, K. K. et al. Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat. Cell Biol. 14, 1282–1294 (2012).
pubmed: 23178882
Peterson, S. C. et al. Basal cell carcinoma preferentially arises from stem cells within hair follicle and mechanosensory niches. Cell Stem Cell 16, 400–412 (2015).
pubmed: 25842978
pmcid: 4387376
Grachtchouk, M. et al. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J. Clin. Invest. 121, 1768–1781 (2011).
pubmed: 21519145
pmcid: 3083781
Youssef, K. K. et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat. Cell. Biol. 12, 299–305 (2010).
pubmed: 20154679
Balmain, A. & Yuspa, S. H. Milestones in skin carcinogenesis: the biology of multistage carcinogenesis. J. Invest. Dermatol. 134, E2–E7 (2014).
pubmed: 25302469
Nassar, D., Latil, M., Boeckx, B., Lambrechts, D. & Blanpain, C. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat. Med. 21, 946–954 (2015).
pubmed: 26168291
Lowry, W. E., Flores, A. & White, A. C. Exploiting mouse models to study ras-induced cutaneous squamous cell carcinoma. J. Invest. Dermatol. 136, 1543–1548 (2016).
pubmed: 27160068
Vitale-Cross, L., Amornphimoltham, P., Fisher, G., Molinolo, A. A. & Gutkind, J. S. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res. 64, 8804–8807 (2004).
pubmed: 15604235
Caulin, C. et al. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res. 64, 5054–5058 (2004).
pubmed: 15289303
Li, S. et al. A keratin 15 containing stem cell population from the hair follicle contributes to squamous papilloma development in the mouse. Mol. Carcinog. 52, 751–759 (2013).
pubmed: 22431489
Lapouge, G. et al. Identifying the cellular origin of squamous skin tumors. Proc. Natl Acad. Sci. USA 108, 7431–7436 (2011).
pubmed: 21502497
White, A. C. et al. Defining the origins of Ras/p53-mediated squamous cell carcinoma. Proc. Natl Acad. Sci. USA. 108, 7425–7430 (2011).
pubmed: 21502519
Boumahdi, S. et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511, 246–250 (2014).
pubmed: 24909994
White, A. C. et al. Stem cell quiescence acts as a tumour suppressor in squamous tumours. Nat. Cell. Biol. 16, 99–107 (2014).
pubmed: 24335650
Vultur, A. & Herlyn, M. SnapShot: melanoma. Cancer Cell. 23, 706–706.e1 (2013).
pubmed: 23680152
Schadendorf, D. et al. Melanoma. Nat. Rev. Dis. Prim. 1, 15003 (2015).
pubmed: 27188223
Marks, R., Dorevitch, A. P. & Mason, G. Do all melanomas come from “moles”? a study of the histological association between melanocytic naevi and melanoma. Australas. J. Dermatol. 31, 77–80 (1990).
pubmed: 2095738
Bevona, C., Goggins, W., Quinn, T., Fullerton, J. & Tsao, H. Cutaneous melanomas associated with nevi. Arch. Dermatol. 139, 1620–1624 (2003). discussion 1624.
pubmed: 14676081
Moon, H. et al. Melanocyte stem cell activation and translocation initiate cutaneous melanoma in response to UV exposure. Cell. Stem Cell. 21, 665–678.e6 (2017).
pubmed: 29033353
pmcid: 9004284
Moon, H. & White, A. C. A path from melanocyte stem cells to cutaneous melanoma illuminated by UVB. Mol. Cell. Oncol. 5, e1409864 (2018).
pubmed: 29487896
pmcid: 5821417
Sun, Q. et al. A novel mouse model demonstrates that oncogenic melanocyte stem cells engender melanoma resembling human disease. Nat. Commun. 10, 5023 (2019).
pubmed: 31685822
pmcid: 6828673
Dankort, D. et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544–552 (2009).
pubmed: 19282848
pmcid: 2705918
Ali, N. et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell 169, 1119–1129.e11 (2017).
pubmed: 28552347
pmcid: 5504703
Mathur, A. N. et al. Treg-cell control of a CXCL5-IL-17 inflammatory axis promotes hair-follicle-stem-cell differentiation during skin-barrier repair. Immunity 50, 655–667.e4 (2019).
pubmed: 30893588
pmcid: 6507428
Goldstein, J. & Horsley, V. Home sweet home: skin stem cell niches. Cell. Mol. Life. Sci. 69, 2573–2582 (2012).
pubmed: 22410738
pmcid: 3449145
Rompolas, P. & Greco, V. Stem cell dynamics in the hair follicle niche. Semin. Cell. Dev. Biol. 25–26, 34–42 (2014).
pubmed: 24361866
Wu, S., Powers, S., Zhu, W. & Hannun, Y. A. Substantial contribution of extrinsic risk factors to cancer development. Nature 529, 43–47 (2016).
pubmed: 26675728
Lee, C. S. et al. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. Nat. Genet. 46, 1060–1062 (2014).
pubmed: 25194279
pmcid: 4324615
Viros, A. et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature 511, 478–482 (2014).
pubmed: 24919155
pmcid: 4112218
Lindberg, M., Boström, M., Elliott, K. & Larsson, E. Intragenomic variability and extended sequence patterns in the mutational signature of ultraviolet light. Proc. Natl Acad. Sci. USA 116, 20411–20417 (2019).
pubmed: 31548379
pmcid: 6789905
Strozyk, E. & Kulms, D. The role of AKT/mTOR pathway in stress response to UV-irradiation: implication in skin carcinogenesis by regulation of apoptosis, autophagy and senescence. Int. J. Mol. Sci. 14, 15260–15285 (2013).
pubmed: 23887651
pmcid: 3759859
Faurschou, A., Haedersdal, M., Poulsen, T. & Wulf, H. C. Squamous cell carcinoma induced by ultraviolet radiation originates from cells of the hair follicle in mice. Exp. Dermatol. 16, 485–489 (2007).
pubmed: 17518988
Elmets, C. A., Ledet, J. J. & Athar, M. Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention. J. Invest. Dermatol. 134, 2497–2502 (2014).
pubmed: 24804836
pmcid: 4165774
Chan, G. et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59, 991–994 (1999).
pubmed: 10070952
Denkert, C. et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 61, 303–308 (2001).
pubmed: 11196178
Thomas, G. J. & Morton, C. A. Cyclooxygenase in cancer prevention and treatments for actinic keratosis. Dermatol. Ther. (Heidelb.) 7, 21–29 (2017).
Sobolewski, C., Cerella, C., Dicato, M., Ghibelli, L. & Diederich, M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int. J. Cell. Biol. 2010, 215158 (2010).
pubmed: 20339581
pmcid: 2841246
Neil, J. R., Johnson, K. M., Nemenoff, R. A. & Schiemann, W. P. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 29, 2227–2235 (2008).
pubmed: 18725385
pmcid: 2577139
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
pubmed: 26343581
pmcid: 4597191
Tang, J. Y. et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev. Res. (Philos. Pa) 3, 25–34 (2010).
Chaudhary, S. C. et al. Naproxen inhibits UVB-induced basal cell and squamous cell carcinoma development in Ptch1+/− /SKH-1 hairless mice. Photochem. Photobiol. 93, 1016–1024 (2017).
pubmed: 28329421
pmcid: 5784408
Muller-Decker, K. et al. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc. Natl Acad. Sci. USA 99, 12483–12488 (2002).
pubmed: 12221288
pmcid: 129471
Tober, K. L. et al. Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J. Invest. Dermatol. 126, 205–211 (2006).
pubmed: 16417238
Sung, Y. M., He, G. & Fischer, S. M. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res. 65, 9304–9311 (2005).
pubmed: 16230392
Sung, Y. M., He, G., Hwang, D. H. & Fischer, S. M. Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene 25, 5507–5516 (2006).
pubmed: 16607275
Simper, M. S. et al. The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin. Mol. Oncol. 8, 1626–1639 (2014).
pubmed: 25034079
pmcid: 4253556
Fischer, S. M. et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinog. 25, 231–240 (1999).
pubmed: 10449029
Pentland, A. P., Schoggins, J. W., Scott, G. A., Khan, K. N. & Han, R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20, 1939–1944 (1999).
pubmed: 10506108
Tiano, H. F. et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62, 3395–3401 (2002).
pubmed: 12067981
Jiao, J. et al. Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer. Mol. Cancer Res. 12, 1677–1688 (2014).
pubmed: 25063587
pmcid: 4233191
Jiao, J. et al. Cell-type-specific roles for COX-2 in UVB-induced skin cancer. Carcinogenesis 35, 1310–1319 (2014).
pubmed: 24469308
pmcid: 4043244
Ishikawa, T. O. & Herschman, H. R. Conditional knockout mouse for tissue-specific disruption of the cyclooxygenase-2 (Cox-2) gene. Genesis 44, 143–149 (2006).
pubmed: 16496341
Moon, H., Kim, D., Donahue, L. R. & White, A. C. Phenotypic plasticity of cutaneous squamous cell carcinoma mediated by cyclooxygenase-2. J. Invest. Dermatol. pii: S0022-202X(20)30051-8 (2020).
Squarize, C. H., Castilho, R. M., Bugge, T. H. & Gutkind, J. S. Accelerated wound healing by mTOR activation in genetically defined mouse models. PLoS ONE 5, e10643 (2010).
pubmed: 20498714
pmcid: 2869363
Greenhough, A. et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30, 377–386 (2009).
pubmed: 19136477
Lasa, M., Abraham, S. M., Boucheron, C., Saklatvala, J. & Clark, A. R. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol. Cell. Biol. 22, 7802–7811 (2002).
pubmed: 12391149
pmcid: 134716
Pineda, C. M. et al. Hair follicle regeneration suppresses Ras-driven oncogenic growth. J. Cell. Biol. 218, 3212–3222 (2019).
pubmed: 31488583
pmcid: 6781447
Futagami, A., Ishizaki, M., Fukuda, Y., Kawana, S. & Yamanaka, N. Wound healing involves induction of cyclooxygenase-2 expression in rat skin. Lab. Invest. 82, 1503–1513 (2002).
pubmed: 12429810
Domper Arnal, M. J., Ferrández Arenas, Á. & Lanas Arbeloa, Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J. Gastroenterol. 21, 7933–7943 (2015).
pubmed: 26185366
pmcid: 4499337
Huang, F. L. & Yu, S. J. Esophageal cancer: risk factors, genetic association, and treatment. Asian J. Surg. 41, 210–215 (2018).
pubmed: 27986415
Lin, E. W., Karakasheva, T. A., Hicks, P. D., Bass, A. J. & Rustgi, A. K. The tumor microenvironment in esophageal cancer. Oncogene 35, 5337–5349 (2016).
pubmed: 26923327
pmcid: 5003768
Xian, W. et al. The cellular origin of barrett’s esophagus and its stem cells. Adv. Exp. Med. Biol. 1123, 55–69 (2019).
pubmed: 31016595
Liu, K. et al. Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer. Cancer Lett. 458, 21–28 (2019).
pubmed: 31125642
pmcid: 6597177
Liu, K. et al. Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell 12, 304–315 (2013).
pubmed: 23472872
pmcid: 3594795
Moon, H., Zhu, J., Donahue, L. R., Choi, E. & White, A. C. Krt5+/Krt15+ foregut basal progenitors give rise to cyclooxygenase-2-dependent tumours in response to gastric acid stress. Nat. Commun. 10, 2225 (2019).
pubmed: 31110179
pmcid: 6527614
Frede, J., Greulich, P., Nagy, T., Simons, B. D. & Jones, P. H. A single dividing cell population with imbalanced fate drives oesophageal tumour growth. Nat. Cell. Biol. 18, 967–978 (2016).
pubmed: 27548914
pmcid: 5870829
Wang, X. et al. Residual embryonic cells as precursors of a Barrett’s-like metaplasia. Cell 145, 1023–1035 (2011).
pubmed: 21703447
pmcid: 3125107
Jiang, M. et al. Transitional basal cells at the squamous-columnar junction generate Barrett’s oesophagus. Nature 550, 529–533 (2017).
pubmed: 29019984
pmcid: 5831195
Runge, T. M., Abrams, J. A. & Shaheen, N. J. Epidemiology of barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol. Clin. North. Am. 44, 203–231 (2015).
pubmed: 26021191
pmcid: 4449458
Abnet, C. C., Arnold, M. & Wei, W. Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360–373 (2018).
pubmed: 28823862
Morita, M. et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int. J. Clin. Oncol. 15, 126–134 (2010).
pubmed: 20224884
Que, J., Garman, K. S., Souza, R. F. & Spechler, S. J. Pathogenesis and cells of origin of barrett’s esophagus. Gastroenterology 157, 349–364.e1 (2019).
pubmed: 31082367
Huang, R. Y. & Chen, G. G. Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim. Biophys. Acta 1815, 158–169 (2011).
pubmed: 21147199
Altorki, N. COX-2: a target for prevention and treatment of esophageal cancer. J. Surg. Res. 117, 114–120 (2004).
pubmed: 15013721
Yu, H. P. et al. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J. Gastroenterol. Hepatol. 19, 638–642 (2004).
pubmed: 15151617
Buttar, N. S. et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology 122, 1101–1112 (2002).
pubmed: 11910360
Li, Z. et al. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 22, 547–551 (2001).
pubmed: 11285187
Stoner, G. D. et al. The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis 26, 1590–1595 (2005).
pubmed: 15878914
Zhi, H. et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 27, 1214–1221 (2006).
pubmed: 16352617
Duggan, S. P. et al. Low pH induces co-ordinate regulation of gene expression in oesophageal cells. Carcinogenesis 27, 319–327 (2006).
pubmed: 16113055
van der Woude, C. J., Kleibeuker, J. H., Jansen, P. L. M. & Moshage, H. Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis 9, 123–130 (2004).
pubmed: 15004509
Fan, Y., Mao, R. & Yang, J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 4, 176–185 (2013).
pubmed: 23483479
pmcid: 4875500
Morris, R. J. et al. Capturing and profiling adult hair follicle stem cells. Nat. Biotechnol. 22, 411–417 (2004).
pubmed: 15024388
Oyama, K. et al. Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide. Nippon. Shokakibyo. Gakkai. Zasshi. 104, 1183–1191 (2007).
pubmed: 17675820
Kaur, B. S. et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett’s esophagus. Gastroenterology 123, 60–67 (2002).
pubmed: 12105834
de Thé, H. Differentiation therapy revisited. Nat. Rev. Cancer 18, 117–127 (2018).
pubmed: 29192213
Wang, H. et al. All-trans retinoic acid and COX-2 cross-talk to regulate BMP9-induced osteogenic differentiation via Wnt/β-catenin in mesenchymal stem cells. Biomed. Pharmacother. 118, 109279 (2019).
pubmed: 31376651
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
Muraoka, N. et al. Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming. Nat. Commun. 10, 674 (2019).
pubmed: 30787297
pmcid: 6382796
Lee, B. C. et al. PGE2 maintains self-renewal of human adult stem cells via EP2-mediated autocrine signaling and its production is regulated by cell-to-cell contact. Sci. Rep. 6, 26298 (2016).
pubmed: 27230257
pmcid: 4882486